The insider sales are routine cashless-exercise dispositions at trivial dollar amounts relative to market cap. No material sell signal. The Q1 earnings decline is the more relevant fundamental story — watch for any further deterioration in Tyvaso franchise pricing/volume trends or the expected commercial supply agreement charge. The upcoming ralinepag DPI Phase 2 readout is the next key catalyst.
Price Chart
Executive Summary
CEO Martine Rothblatt, CFO James Edgemond, and Director Nilda Mesa sold a total of ~$1.03M in UTHR shares over the past week, overwhelmingly driven by CEO Rothblatt's option exercises and same-day sales. The sales follow Q1 earnings (May 6) showing a 2% YoY revenue decline and 15% net income drop — a negative report that could naturally trigger normal portfolio rebalancing. At just ~0.004% of UTHR's $24.1B market cap, the cluster is economically trivial and entirely consistent with routine option-cash exercises, not a bearish signal.
Key Financial Metrics
Key Facts
- Three insiders (CEO, CFO, Director) sold shares in aggregate sold only ~$1.03M in open-market sales — just 0.004% of UTHR's $24.1B market cap
- CEO Martine Rothblatt accounted for ~$1.79M of the $1.98M in gross open-market sales volume; her sales were all same-day dispositions following option exercises at exercise prices of $146.03 or $0, consistent with routine cashless exercises
- CFO Edgemond sold a token 80 shares ($45K) and Director Mesa sold 258 shares ($150K) — immaterial amounts
- COO Michael Benkowitz gifted 11,728 shares ($0) — non-economic event
- Q1 2026 revenues fell 2% YoY to $781.5M and net income fell 15% to $274.9M; Tyvaso DPI grew 9% but Nebulized Tyvaso declined 22%
- Cluster occurred 12 days after earnings — well within the normal trading window after a blackout lift
Financial Impact
$1.03M in open-market sales, ~0.004% of market cap — negligible economic impact
Risk Factors
- Q1 revenue decline could continue into pressure on growth expectations for Tyvaso franchise
- Commercial supply agreement reserve of $26.8M may recur if inventory levels remain elevated
- Competitive dynamics in inhaled prostacyclins remain dynamic per management's own language
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1779142716684 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $500.35 $497.31 | ▼ −0.61% | ▼ −2.72% | $571.38 (+14.20%) |
Sep 11, 2026 21d ago | Insider Cluster | $497.11 $494.63 | ▼ −0.50% | ▼ −0.28% | $571.38 (+14.94%) |
Sep 10, 2026 22d ago | Insider Cluster | $503.86 $497.27 | ▼ −1.31% | ▼ −0.81% | $571.38 (+13.40%) |
Sep 9, 2026 23d ago | Insider Cluster | $506.82 $498.48 | ▼ −1.65% | ▼ −0.99% | $571.38 (+12.74%) |
Sep 4, 2026 28d ago | Insider Cluster | $487.61 $502.70 | ▲ +3.09% | ▲ +4.30% | $571.38 (+17.18%) |
Sep 3, 2026 29d ago | Insider Cluster | $488.16 $497.11 | ▲ +1.83% | ▲ +2.98% | $571.38 (+17.05%) |
Aug 28, 2026 5w ago | Insider Cluster | $515.46 $487.61 | ▼ −5.40% | ▼ −5.51% | $571.38 (+10.85%) |
Aug 27, 2026 5w ago | Insider Cluster | $527.91 $492.02 | ▼ −6.80% | ▼ −6.03% | $571.38 (+8.23%) |
Aug 26, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
Aug 25, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access